Peptide epitope identification for tumor-reactive CD4 T cells

Hiroya Kobayashi, Esteban Celis

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Because T lymphocytes have the capacity to recognize tumor cells, significant efforts are being devoted towards the development of T cell-based immunotherapy for cancer. Most of this work has centered in the induction of anti-tumor CD8 T cells, which exhibit cytolytic activity towards tumor cells expressing tumor-specific or tumor associated antigens. Unfortunately to this day, T cell-based immunotherapy for cancer remains suboptimal. One of the possible explanations is that these immunotherapies have ignored the role that CD4 T helper lymphocytes play in the generation and persistence of CD8 T cell responses. Thus, we believe that in order to obtain clinical benefits T cell-based immunotherapy must stimulate both CD8 and CD4 tumor-reactive T cell responses. During the past seven years our group has focused on the identification of CD4 T cell epitopes from tumor-associated and tumor-specific antigens that could be used to complement the already identified CD8 T cell epitopes to produce effective vaccination strategies against numerous tumor types. We will describe here the strategy we used that resulted in the identification and characterization of numerous CD4 T cell epitopes that are applicable to developing therapies against hematological malignancies and solid tumors.

Original languageEnglish (US)
Pages (from-to)221-227
Number of pages7
JournalCurrent Opinion in Immunology
Volume20
Issue number2
DOIs
StatePublished - Apr 1 2008

Fingerprint

Epitopes
T-Lymphocytes
Peptides
Neoplasms
Immunotherapy
T-Lymphocyte Epitopes
Neoplasm Antigens
Hematologic Neoplasms
Helper-Inducer T-Lymphocytes
Vaccination

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Peptide epitope identification for tumor-reactive CD4 T cells. / Kobayashi, Hiroya; Celis, Esteban.

In: Current Opinion in Immunology, Vol. 20, No. 2, 01.04.2008, p. 221-227.

Research output: Contribution to journalReview article

@article{287d5b92056146febb04e9baa413734f,
title = "Peptide epitope identification for tumor-reactive CD4 T cells",
abstract = "Because T lymphocytes have the capacity to recognize tumor cells, significant efforts are being devoted towards the development of T cell-based immunotherapy for cancer. Most of this work has centered in the induction of anti-tumor CD8 T cells, which exhibit cytolytic activity towards tumor cells expressing tumor-specific or tumor associated antigens. Unfortunately to this day, T cell-based immunotherapy for cancer remains suboptimal. One of the possible explanations is that these immunotherapies have ignored the role that CD4 T helper lymphocytes play in the generation and persistence of CD8 T cell responses. Thus, we believe that in order to obtain clinical benefits T cell-based immunotherapy must stimulate both CD8 and CD4 tumor-reactive T cell responses. During the past seven years our group has focused on the identification of CD4 T cell epitopes from tumor-associated and tumor-specific antigens that could be used to complement the already identified CD8 T cell epitopes to produce effective vaccination strategies against numerous tumor types. We will describe here the strategy we used that resulted in the identification and characterization of numerous CD4 T cell epitopes that are applicable to developing therapies against hematological malignancies and solid tumors.",
author = "Hiroya Kobayashi and Esteban Celis",
year = "2008",
month = "4",
day = "1",
doi = "10.1016/j.coi.2008.04.011",
language = "English (US)",
volume = "20",
pages = "221--227",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Peptide epitope identification for tumor-reactive CD4 T cells

AU - Kobayashi, Hiroya

AU - Celis, Esteban

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Because T lymphocytes have the capacity to recognize tumor cells, significant efforts are being devoted towards the development of T cell-based immunotherapy for cancer. Most of this work has centered in the induction of anti-tumor CD8 T cells, which exhibit cytolytic activity towards tumor cells expressing tumor-specific or tumor associated antigens. Unfortunately to this day, T cell-based immunotherapy for cancer remains suboptimal. One of the possible explanations is that these immunotherapies have ignored the role that CD4 T helper lymphocytes play in the generation and persistence of CD8 T cell responses. Thus, we believe that in order to obtain clinical benefits T cell-based immunotherapy must stimulate both CD8 and CD4 tumor-reactive T cell responses. During the past seven years our group has focused on the identification of CD4 T cell epitopes from tumor-associated and tumor-specific antigens that could be used to complement the already identified CD8 T cell epitopes to produce effective vaccination strategies against numerous tumor types. We will describe here the strategy we used that resulted in the identification and characterization of numerous CD4 T cell epitopes that are applicable to developing therapies against hematological malignancies and solid tumors.

AB - Because T lymphocytes have the capacity to recognize tumor cells, significant efforts are being devoted towards the development of T cell-based immunotherapy for cancer. Most of this work has centered in the induction of anti-tumor CD8 T cells, which exhibit cytolytic activity towards tumor cells expressing tumor-specific or tumor associated antigens. Unfortunately to this day, T cell-based immunotherapy for cancer remains suboptimal. One of the possible explanations is that these immunotherapies have ignored the role that CD4 T helper lymphocytes play in the generation and persistence of CD8 T cell responses. Thus, we believe that in order to obtain clinical benefits T cell-based immunotherapy must stimulate both CD8 and CD4 tumor-reactive T cell responses. During the past seven years our group has focused on the identification of CD4 T cell epitopes from tumor-associated and tumor-specific antigens that could be used to complement the already identified CD8 T cell epitopes to produce effective vaccination strategies against numerous tumor types. We will describe here the strategy we used that resulted in the identification and characterization of numerous CD4 T cell epitopes that are applicable to developing therapies against hematological malignancies and solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=44749086558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44749086558&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2008.04.011

DO - 10.1016/j.coi.2008.04.011

M3 - Review article

C2 - 18499419

AN - SCOPUS:44749086558

VL - 20

SP - 221

EP - 227

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

IS - 2

ER -